ATE482271T1 - Lna-oligonukleotide und krebsbehandlung - Google Patents

Lna-oligonukleotide und krebsbehandlung

Info

Publication number
ATE482271T1
ATE482271T1 AT05800759T AT05800759T ATE482271T1 AT E482271 T1 ATE482271 T1 AT E482271T1 AT 05800759 T AT05800759 T AT 05800759T AT 05800759 T AT05800759 T AT 05800759T AT E482271 T1 ATE482271 T1 AT E482271T1
Authority
AT
Austria
Prior art keywords
lna
beta
oligonucleotides
inhibition
lna oligonucleotides
Prior art date
Application number
AT05800759T
Other languages
English (en)
Inventor
Lene Sonderbye Kjfrulff
Marlene Asklund
Majken Westergaard
Christoph Rosenbohm
Margit Wissenbach
Bo Hansen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Priority claimed from PCT/DK2005/000719 external-priority patent/WO2006050732A2/en
Application granted granted Critical
Publication of ATE482271T1 publication Critical patent/ATE482271T1/de

Links

AT05800759T 2004-11-09 2005-11-09 Lna-oligonukleotide und krebsbehandlung ATE482271T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62656104P 2004-11-09 2004-11-09
DKPA200401728 2004-11-09
PCT/DK2005/000719 WO2006050732A2 (en) 2004-11-09 2005-11-09 Lna oligonucleotides and the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE482271T1 true ATE482271T1 (de) 2010-10-15

Family

ID=38965697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05800759T ATE482271T1 (de) 2004-11-09 2005-11-09 Lna-oligonukleotide und krebsbehandlung

Country Status (6)

Country Link
CN (1) CN101065485B (de)
AT (1) ATE482271T1 (de)
DE (1) DE602005023772D1 (de)
DK (1) DK1824975T3 (de)
ES (1) ES2353638T3 (de)
ZA (1) ZA200704254B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294870A1 (en) * 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100782896B1 (ko) * 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
WO2003091384A2 (en) * 2002-04-24 2003-11-06 Eirx Therapeutics Limited A role for survivin in apoptosis of myeloid cells
DE602004022020D1 (de) * 2003-02-10 2009-08-27 Santaris Pharma As Oligomere verbindungen zur modulation der expression von survivin

Also Published As

Publication number Publication date
CN101065485A (zh) 2007-10-31
ES2353638T3 (es) 2011-03-03
DK1824975T3 (da) 2011-06-06
ZA200704254B (en) 2009-09-30
ES2353638T9 (es) 2011-06-16
DE602005023772D1 (de) 2010-11-04
CN101065485B (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
WO2006050732A3 (en) Lna oligonucleotides and the treatment of cancer
Han et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells
Lim et al. Effects of flavonoids on senescence-associated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts
Xu et al. Chromones from the endophytic fungus Pestalotiopsis sp. isolated from the Chinese mangrove plant Rhizophora mucronata
Juvale et al. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2
Gaur et al. Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity
Lee et al. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells
Beillerot et al. Synthesis and protective effects of coumarin derivatives against oxidative stress induced by doxorubicin
Mischenko et al. Echinamines A and B, First Aminated Hydroxynaphthazarins from the Sea Urchin Scaphechinus m irabilis
MX2007013632A (es) Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo y sus productos intermedios.
Kim et al. Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production
Kang et al. Early growth response protein 1 upregulation and nuclear translocation by 2′-benzoyloxycinnamaldehyde induces prostate cancer cell death
Cuong et al. Anti-inflammatory activity of phenolic compounds from the whole plant of Scutellaria indica
Macan et al. Antitumor and antiviral activities of 4-substituted 1, 2, 3-triazolyl-2, 3-dibenzyl-L-ascorbic acid derivatives
Wang et al. Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma
Huang et al. Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
Ke et al. Design, synthesis and biological mechanisms research on 1, 2, 3-triazole derivatives of Jiyuan Oridonin A
Xue et al. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies
Zi et al. Design, synthesis, and biological evaluation of novel biotinylated podophyllotoxin derivatives as potential antitumor agents
Hegde et al. New potential antitumor compounds from the plant Aristolochia manshuriensis as inhibitors of the CDK2 enzyme
Zhang et al. Licochalcone A restrains microphthalmia‐associated transcription factor expression and growth by activating autophagy in melanoma cells via miR‐142‐3p/Rheb/mTOR pathway
Kim et al. Synthesis and biological evaluation of 4′-substituted kaempfer-3-ols
ATE482271T1 (de) Lna-oligonukleotide und krebsbehandlung
Wang et al. CASC15: A tumor-associated long non-coding RNA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties